ReGEN Biomedical
At ReGEN Biomedical, our mission is to propel the field of regenerative medicine forward by developing the next generation of automated cell and tissue manufacturing technologies. Building on the success of our GEN 1.0 tissue manufacturing platform, now open for use and partnerships, we are advancing GEN 2.0. This next-generation equipment is designed to address the evolving demands of the biomedical industry. With a focus on affordability, reproducibility, and scalability, we aim to transform manufacturing paradigms and make cutting-edge cellular therapies accessible to patients worldwide through strategic sales and licensing opportunities.
Work in m2M
ReGEN Biomedical will participate in the m2M project by developing an automated platform to generate phenotypically distinct microtissues in a high-throughput manner. These microtissues will be quality controlled and different strategies to store them and transported will be evaluated. The manufacturing of these microtissues will be further investigated by various processes such as culturing cells with serum replacements and pre-selecting cells using MACS technology. Furthermore, ReGEN will be assisting in the GMP translation as well as production and process validation preparation for GMP approval.
Researchers involved
